Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

Docetaxel (Taxotere®), alone or in combination with other anticancer agents, has proven efficacy in the first- and second-line treatment of metastatic breast cancer. This phase II study investigated the efficacy and tolerability of docetaxel as neoadjuvant chemotherapy in women with stage II–III pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Amat, S, Bougnoux, P, Penault-Llorca, F, Fétissof, F, Curé, H, Kwiatkowski, F, Achard, J-L, Body, G, Dauplat, J, Chollet, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741049/
https://www.ncbi.nlm.nih.gov/pubmed/12778058
http://dx.doi.org/10.1038/sj.bjc.6600916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741049/
https://www.ncbi.nlm.nih.gov/pubmed/12778058
http://dx.doi.org/10.1038/sj.bjc.6600916

Ejemplares similares